Written By: Chris Sellers, RPh Area Manager, Texas Oncology
Download Here

The purpose is to provide management of common adverse events, follow-up with patients and dose modifications. Dose adjustments are common and greatly reduced frequency and severity of adverse reactions.  Continue reading NSCLC Afatinib Management

Read More

Written by Julianne Orr, PharmD
Download Here

Olanzapine is an FDA approved atypical antipsychotic that blocks multiple neuronal receptors involved in nausea/vomiting pathways1. Olanzapine has been studied for breakthrough2 CINV aswell as prophylaxis of highly and moderately emetogenic regimens3,4,5. Continue reading Olanzapine Use in Chemotherapy Induced Nausea and Vomiting (CINV)

Read More

Written by: Joshua Nubla, PharmD NCODA- Assistant Manager
Download Here

Combinations of fluid hydration therapies, antimotility agents such as loperamide, and dose modifications can be used for patients undergoing chemotherapy induced diarrhea which is problematic in numerous therapy regimens. Continue reading Chemotherapy Induced Diarrhea

Read More